Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study

Fukunaga, Shuji; Nakano, Dan; Kawaguchi, Takumi; Eslam, Mohammed; Ouchi, Akihiro; Nagata, Tsutomu; Kuroki, Hidefumi; Kawata, Hidemichi; Abe, Hirohiko; Nouno, Ryuichi; Kawaguchi, Koutaro; George, Jacob; Mitsuyama, Keiichi; Torimura, Takuji

doi:10.3390/ijms22115462

Cited by 37 publications

(40 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lin et al [ 67 ] evaluated the impact of MAFLD on the recurrence of HBV-related HCC after curative resection and found that lean/normal weight MAFLD was a risk factor for tumor recurrence among patients with MAFLD (hazard ratio [HR], 2.030; 95% confidence interval [CI], 1.117–3.690; P =0.020) ( Table 1 ). Fukunaga et al [ 42 ] investigated the impact of MAFLD on the prevalence of colorectal adenoma in health check-up examinees. The authors demonstrated that lean/normal-weight MAFLD was the sole independent factor associated with the presence of colorectal adenoma (odds ratio [OR], 3.351; 95% CI, 1.589–7.262; P ≤0.001).…”

Section: Validity Of the Mafld Definition For People Who Are Lean/nor...mentioning

confidence: 99%

“…The authors demonstrated that lean/normal-weight MAFLD was the sole independent factor associated with the presence of colorectal adenoma (odds ratio [OR], 3.351; 95% CI, 1.589–7.262; P ≤0.001). Lean/normal weight MAFLD was also the most important classifier for the presence of colorectal adenoma in data-mining analysis [ 42 ]. Semmler et al [ 68 ] investigated the relevance of MAFLD for mortality and demonstrated that lean/normal-weight MAFLD had the worst survival rates.…”

Section: Validity Of the Mafld Definition For People Who Are Lean/nor...mentioning

confidence: 99%

See 1 more Smart Citation

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

et al. 2022

Self Cite

View full text Add to dashboard Cite

Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight individuals. However, there is no standard definition of this unique phenotype. Second, fatty liver is often observed in patients with concomitant viral hepatitis. The exclusion of viral hepatitis from non-alcoholic fatty liver disease limits its value and detracts from the investigation and holistic management of coexisting fatty liver in patients with viral hepatitis. Third, fatty liver-associated hepatocellular carcinoma (HCC) is generally categorized as non-B non-C HCC. Fourth, the population is aging rapidly, and it is imperative to develop a practicable, low-intensity exercise program for elderly patients. Fifth, most patients and nonspecialized healthcare professionals still lack an awareness of the significance of fatty liver both in terms of intrahepatic and extrahepatic disease and cancer. Recently, an international expert panel proposed a new definition of fatty liver: metabolic dysfunction-associated fatty liver disease (MAFLD). One feature of MAFLD is that metabolic dysfunction is a prerequisite for diagnosis. Pertinent to regional issues, MAFLD also provides its diagnostic criteria in lean/normal-weight individuals. Furthermore, MAFLD is independent of any concomitant liver disease, including viral hepatitis. Therefore, MAFLD may be a more suitable definition for fatty liver in the Asia-Pacific region. In this review, we introduce the regional characteristics of fatty liver and discuss the advantages of MAFLD for improving clinical practice for liver disease in the region.

show abstract

Section: Validity Of the Mafld Definition For People Who Are Lean/nor...mentioning

confidence: 99%

Section: Validity Of the Mafld Definition For People Who Are Lean/nor...mentioning

confidence: 99%

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In conclusion, in line with the results reported by Yu et al ., 1 our data show that patients with MAFLD but not NAFLD only experienced significant impairment in HRQOL and performance of physical activities than healthy controls. This study adds to the growing body of evidence demonstrating the utility of the novel MAFLD definition 4 , 5 to identify patients at high risk of hepatic fibrosis, cardiovascular disease, chronic kidney disease, colonic polyps, and mortality 6 – 9 and the importance of consideration of MAFLD criteria in the clinical management of fatty liver disease. 10 – 12 …”

mentioning

confidence: 92%

MAFLD Not NAFLD is Associated with Impairment of Health-related Quality of Life

Attia¹,

Aty²,

Shawket³

et al. 2021

J Clin Transl Hepatol

View full text Add to dashboard Cite

“…104,105 Among patients with NAFLD, the overall risk was higher for right colon tumors than for left colon tumors. 106 Fukugana et al 107 recently demonstrated that MAFLD more accurately identifies colorectal adenoma than does NAFLD. Specifically, non-obese MAFLD is an independent factor for the presence of colorectal adenomas.…”

Section: Extrahepatic Malignanciesmentioning

confidence: 99%

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver

Kaya¹,

Yılmaz²

2021

J Clin Transl Hepatol

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is a multisystemic clinical condition that presents with a wide spectrum of extrahepatic manifestations, such as obesity, type 2 diabetes mellitus, metabolic syndrome, cardiovascular diseases, chronic kidney disease, extrahepatic malignancies, cognitive disorders, and polycystic ovarian syndrome. Among NAFLD patients, the most common mortality etiology is cardiovascular disorders, followed by extrahepatic malignancies, diabetes mellitus, and liver-related complications. Furthermore, the severity of extrahepatic diseases is parallel to the severity of NAFLD. In clinical practice, awareness of the associations of concomitant diseases is of major importance for initiating prompt and timely screening and multidisciplinary management of the disease spectrum. In 2020, a consensus from 22 countries redefined the disease as metabolic (dysfunction)-associated fatty liver disease (MAFLD), which resulted in the redefinition of the corresponding population. Although the patients diagnosed with MAFLD and NAFLD mostly overlap, the MAFLD and NAFLD populations are not identical. In this review, we compared the associations of key extrahepatic diseases between NAFLD and MAFLD.

show abstract

Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study

Cited by 37 publications

References 45 publications

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

MAFLD Not NAFLD is Associated with Impairment of Health-related Quality of Life

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver

Contact Info

Product

Resources

About